

RECEPTOR-SELECTIVE NSAID MEDICATIONS OR NSAID COMBINATIONS CRITERIA

Pharmacology:

Two COX isoenzymes have been identified: COX-1 and COX-2. COX-2's main function is induced during pain and inflammatory stimuli. The mechanism of action of celecoxib and meloxicam is primarily selective inhibition of COX-2 in the treatment of pain and inflammation.

Medications:

Brand Names	Generic Names	Dosage Strengths
Celebrex [®]	celecoxib	100mg, 200mg, 400mg
Mobic [®]	meloxicam	7.5mg, 15mg
Vimovo [®]	EC naproxen/ IR esomeprazole	375mg/20mg, 500mg/20mg tablets
Vivlodex [™]	meloxicam	5mg, 10mg

Criteria for Approval:

- A. Patient is of FDA approved age for medication requested, **OR**
- B. Patient has failed or is intolerant to 2 or more non-selective NSAIDs, one of which must be etodolac, disulfiram, diclofenac, or piroxicam, **AND**
- C. Non-Preferred drugs on the Preferred Drug List (PDL) require failure on Preferred drugs first

Criteria for Denial:

- A. Prior approval will be denied if the approval criteria are not met.
- B. Contraindication to Celebrex[®]: Sulfonamide allergy.
- C. Perioperative period for coronary artery bypass graft (CABG) surgery.
- D. Concomitant use of warfarin or another NSAID.

Length of Approval: 1 year

References:

Available upon request.

Committee Review:	Reason for Review:	Date Approved:
Pharmacy & Therapeutic Committee	New	09/01
Pharmacy & Therapeutic Committee	Pursuant to Chapter 281, NH law 2001	10/02
Pharmacy & Therapeutic Committee	Update	3/24/05
Commissioner	Approval	4/15/05
DUR Board	Update	6/22/10
Commissioner	Approval	8/3/10
DUR Board	Update	10/11/16
Commissioner	Approval	11/22/16
DUR Board	Update	9/27/18
Commissioner Designee	Approval	11/27/18